Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22412510 | 1.00 | LMNA (0.41) | LMNAL3MBTL1TDP1MPIPDE4A | |
| SCHEMBL9736991 | 1.00 | LMNA (0.41) | LMNAL3MBTL1TDP1MPIPDE4A | |
| SCHEMBL129544 | 1.00 | LMNA (0.41) | LMNAL3MBTL1TDP1MPIPDE4A | |
| SCHEMBL8057 | 1.00 | LMNA (0.41) | LMNAL3MBTL1TDP1MPIPDE4A | |
| SCHEMBL3397672 | 1.00 | LMNA (0.41) | LMNAL3MBTL1TDP1MPIPDE4A | |
| SCHEMBL9737359 | 1.00 | LMNA (0.41) | LMNAL3MBTL1TDP1MPIPDE4A | |
| SCHEMBL187554 | 1.00 | LMNA (0.41) | LMNAL3MBTL1TDP1MPIPDE4A | |
| SCHEMBL9737508 | 1.00 | LMNA (0.41) | LMNAL3MBTL1TDP1MPIPDE4A | |
| SCHEMBL2387363 | 0.98 | LMNA (0.39) | LMNAL3MBTL1TDP1MPIPDE4A | |
| SCHEMBL9736985 | 0.98 | TDP1 (0.43) | LMNAL3MBTL1TDP1MPIPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1009 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122071711-A | Platycodon phosphomannose mutase gene PgPMM, coded product and application thereof | 安徽中医药大学 | 2026-05-22 | — | — | CN | claimed |
| CN-120137865-A | Genetically engineered bacterium for producing lactose-N-disaccharide, preparation method and application thereof | 汤臣倍健股份有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-119570647-A | Genetically engineered bacterium for producing 2' -fucosyllactose based on mannitol, construction method and application thereof | 山东大学 | 2025-03-07 | — | — | CN | claimed |
| CN-119552791-A | Engineering escherichia coli for producing L-fucose and application thereof | 江南大学 | 2025-03-04 | — | — | CN | claimed |
| CN-118931812-B | Escherichia coli for high-yield fucose and construction method and application thereof | 合肥中科健康生物产业技术研究院有限公司 | 2025-03-04 | — | — | CN | claimed |
| CN-119307432-A | Escherichia coli for high yield of 2' -fucosyllactose, and construction method and application thereof | 南京工业大学 | 2025-01-14 | — | — | CN | claimed |
| CN-119162072-A | Engineering bacterium for reducing lactose residue in fucose synthesis process and construction method and application thereof | 合肥中科健康生物产业技术研究院有限公司 | 2024-12-20 | — | — | CN | claimed |
| CN-112513282-B | Method for producing fructose-6-phosphate from dihydroxyacetone phosphate and glyceraldehyde-3-phosphate | 环球生物能源公司 | 2024-12-13 | — | — | CN | claimed |
| CN-119101640-A | Genetically engineered bacterium for synthesizing N-acetylglucosamine as well as preparation method and application thereof | 汤臣倍健股份有限公司 | 2024-12-10 | — | — | CN | claimed |
| CN-119081982-A | Engineering bacterium for synthesizing fucose by taking 3-fucosyllactose as precursor, construction method and application thereof | 合肥中科健康生物产业技术研究院有限公司 | 2024-12-06 | — | — | CN | claimed |
| EP-1750725-A1 | COMPOSITIONS COMPRISING MANNOSE PHOSPHATE FOR VAGINAL TREATMENT | Kimberly Clark Worldwide, Inc. (US) | 2007-02-14 | — | — | EP | claimed |
| EP-1416904-A4 | METHOD OF SKIN EXFOLIATION | COLOR ACCESS INC (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005094840-A1 | COMPOSITIONS COMPRISING MANNOSE PHOSPHATE FOR VAGINAL TREATMENT | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2005-10-13 | — | — | WO | claimed |
| US-20050203032-A1 | Compositions for vaginal treatment | KIMBERLY-CLARK WORLDWIDE, INC. | 2005-09-15 | — | — | US | claimed |
| US-20050042705-A1 | Methods for the identification of inhibitors of mannosyltransferase as antibiotics | ICORIA, INC. | 2005-02-24 | — | — | US | claimed |
| WO-2005012544-A2 | METHODS FOR THE IDENTIFICATION OF INHIBITORS OF MANNOSYLTRANSFERASE AND MANNOSYLTRANSFERASE COMPLEX SUBUNIT AS ANTIBIOTICS | PARADIGM GENETICS, INC. (US) | 2005-02-10 | — | — | WO | claimed |
| EP-1416904-A1 | METHOD OF SKIN EXFOLIATION | Color Access, Inc. (US) | 2004-05-12 | — | — | EP | claimed |
| WO-2003013448-A1 | METHOD OF SKIN EXFOLIATION | COLOR ACCESS, INC. (US) | 2003-02-20 | — | — | WO | claimed |
| EP-0429522-B1 | PHOSPHOSUGAR-BASED ANTI-INFLAMMATORY AND/OR IMMUNOSUPPRESSIVE DRUGS | UNIV AUSTRALIAN (AU) | 1996-06-26 | — | — | EP | claimed |
| US-5506210-A | Phosphosugar-based anti-inflammatory and/or immunosuppressive drugs | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1996-04-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203032-A1 | Compositions for vaginal treatment | MAN2A1, MUC1, MAN2B2 | LMNA 2586/4885L3MBTL1 4786/4885TDP1 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.